Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06514261 · ClinicalTrials.gov registry record · Phase 1

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

A Phase 1 study of Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
45
Enrollment target
4
Study locations

NCT06514261 is a Phase 1 study of Acute Myeloid Leukemia that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06514261, a Phase 1 study of Acute Myeloid Leukemia, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
4
Study locations

Study Summary

This phase I trial tests safety, side effects and best dose of iadademstat with azacitidine and venetoclax for the treatment of patients with acute myeloid leukemia (AML) who have not received treatment (treatment naive). Chemotherapy drugs, such as iadademstat and azacitidine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving iadademstat with azacitidine and venetoclax may be safe and tolerable in treating patients with treatment naive AML.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • DRUG Azacitidine
  • PROCEDURE Buccal Swab

Study Locations (4)

California

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange

Ohio

  • University of Cincinnati Cancer Center-UC Medical Center - Cincinnati

Pennsylvania

  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2024-12-18
Est. Completion 2026-09-16
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06514261

The ClinicalTrials.gov registry entry for NCT06514261 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (61% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT06514261 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06514261 about?

NCT06514261 is a clinical study titled "Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML". This phase I trial tests safety, side effects and best dose of iadademstat with azacitidine and venetoclax for the treatment of patients with acute myeloid leukemia (AML) who have not received treatment (treatment naive). Chemotherapy drugs, such as iadademstat and azacitidine work in different ways...

What is the current status of trial NCT06514261?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-12-18. Estimated completion is 2026-09-16.

What conditions does trial NCT06514261 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT06514261?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Azacitidine (DRUG), Buccal Swab (PROCEDURE).

Who is sponsoring clinical trial NCT06514261?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06514261 being conducted?

This trial has 4 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.